Search for: "Boehringer Ingelheim Pharmaceutical, Inc" Results 21 - 40 of 87
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
31 May 2010, 8:52 pm by Patent Docs
Intervet Inc. et al. 1:10-cv-00435; filed May 25, 2010 in the District Court of Delaware • Plaintiff: Wyeth LLC • Defendants: Intervet Inc. d/b/a Intervet/Schering-Plough Animal Health; Boehringer Ingelheim Vetmedica Inc. [read post]
13 Feb 2014, 6:00 am by LTA-Editor
District Court Judge David Herndon from the Southern District of Illinois imposed close to $1 million in punitive damages on defendants Boehringer Ingelheim International GMBH (“BII”) and Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
17 Dec 2010, 11:05 am by Bexis
Boehringer Ingelheim Pharmaceuticals, Inc., slip op. (8th Cir. [read post]
26 Oct 2017, 11:07 am by Jennifer Jordan, JD, MSCC
Boehringer Ingelheim Pharmaceuticals, Inc., et al. was dismissed for lack of standing on October 10, 2017. [read post]
9 Jul 2018, 6:30 pm by Todd Presnell
Boehringer Ingelheim Pharmaceuticals, Inc., 2018 WL 3028972 (CADC June 19, 2018). [read post]
9 Jul 2018, 6:30 pm by Todd Presnell
Boehringer Ingelheim Pharmaceuticals, Inc., 2018 WL 3028972 (CADC June 19, 2018). [read post]
15 Jan 2014, 5:43 am by Robert Kreisman
Herndon of the Southern District of Illinois has ordered that Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
19 Dec 2010, 9:44 am
--Naik v Boehringer Ingelheim Pharm, Inc., 7thCir, November 22, 2010, No. 09-2960: Summary judgment upheld for employer after 53-year-old former pharmaceutical sales rep failed to show that termination based on falsification of call records, was pretext for age and national origin (Indian) discrimination in violation of the Age Discrimination in Employment Act (ADEA) and Title VII.The employer's legitimate non-discriminatory reason (LNDR) was pretty damning… [read post]
14 Mar 2012, 10:42 am
Boehringer Ingelheim Pharmaceuticals Inc., et al.; U.S. [read post]
28 Jul 2011, 11:19 am by Bexis
Boehringer Ingelheim Pharmaceuticals, No. 10-3129, slip op. (8th Cir. [read post]
10 Dec 2012, 2:50 pm by Tom Lamb
In the first part of December 2012 Boehringer Ingelheim Pharmaceuticals, Inc., the drug company responsible for Pradaxa, seems to be trying to assure doctors and patients that its relatively new, and certainly controversial, blood thinner medication is safe. [read post]
20 Aug 2012, 11:15 am by Tom Lamb
Since coming on the market in October 2010 the FDA has received numerous Adverse Event Reports involving: • Serious bleeding side effects • Hemorrhages such as hemorrhagic stroke In addition, some medical studies have associated Pradaxa with an increased risk: • Heart attack • Myocardial infarction (MI)• Acute coronary syndrome (ACS) Due to these serious side effects, a growing number of personal injury and wrongful death Pradaxa lawsuits have been filed against these defendants:… [read post]
11 Jan 2018, 12:30 pm by Tom Lamb
Boehringer Ingelheim Pharmaceuticals, Inc. is the drug company responsible for OFEV in the US. [read post]
17 Jan 2007, 5:24 am
The companies that have been sued to date are Amgen, Inc.; Astrazeneca Pharmaceuticals, L.P.; Bayer Corp.; Boehringer-Ingelheim Corp.; Eli Lilly, & Co.; GlaxoSmithKline, PLC; Hoffman-LaRoche, Inc.; Johnson & Johnson; Pfizer, Inc.; and Sanofi-Aventis U.S., Inc.Plaintiffs' claim in these cases is that the defendant erroneously classified pharmaceutical sales representatives as exempt from federal or state overtime… [read post]
13 Jul 2016, 1:56 pm by Tom Lamb
About a month later, however, only those three diabetes drugs from Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
29 Nov 2017, 3:29 am
In re Boehringer Ingelheim Pharmaceuticals, Inc., Serial No. 86852106 (November 27, 2017) [not precedential] (Opinion by Judge Frances Wolfson).The Board ignored applicant's feeble double entendre argument, but it agreed with applicant that the USPTO's evidence failed to show that the term "breathless" merely describes the subject services. [read post]
7 Dec 2010, 2:43 am by Ben Vernia
As for Roxane: Roxane is paying $280 million to resolve claims against it and related entities (Roxane Laboratories Inc., Boehringer Ingelheim Corp. and Boehringer Ingelheim Pharmaceuticals Inc.). [read post]